Century Therapeutics, Inc. IPSC 深 沪
等待开盘 05-21 09:30:00 美东时间
2.25
+0.130
+6.13%
华盛通- 最 高2.26
- 今 开2.15
- 成交量 49.63万股
- 最 低 2.12
- 昨 收 2.12
- 总市值 4.06亿
- 52周最高 3.04
- 市盈率 静 --
- 换手率 0.28%
- 52周最低 0.435
- 委 比 76.01%
- 总股本 1.80亿
- 历史最高 32.899
- 量 比 0.55
- 振 幅 6.60%
- 历史最低 0.3418
- 每 手 1
- 风险率 0.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
US stock futures higher, Lowe's shares fall after reporting earnings. Other stocks declining in pre-market trading. Photo via Shutterstock
05-20 20:05
Century Therapeutics Q1 EPS $(0.11) Beats $(0.17) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 31.25 percent. This is a 112.36 percent decrease over earnings of $0.89 per share
05-13 20:20
Century Therapeutics To Highlight CNTY-813, iPSC-Derived Islet Cell Replacement Therapy Program Engineered With Allo-Evasion 5.0 For Patients With Type 1 Diabetes At ADA 86th Scientific Sessions
Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today
05-01 04:27
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
Arrowhead Pharmaceuticals To Rally Over 44%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts update ratings on top names. B of A Sec raised CMS Energy Corp's price target to $88, Goldman Sachs raised Ramaco Resources Inc's target to $15, Truist Sec cut Packaging Corp's target to $260, Baird cut Mohawk Industries Inc's target to $118, Needham raised Crocs Inc's target to $132, HC Wainwright raised Century Therapeutics Inc's target to $5, and Morgan Stanley raised Arrowhead Pharmaceuticals Inc&#
04-21 19:56
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and raises the price target from $2 to $5.
04-21 18:49
Century Therapeutics Maintains $150M ATM Program, With $131.6M Remaining In Capacity
Other Events. On July 10, 2025, Century Therapeutics, Inc. (the "Company") filed with the Securities and Exchange Commission (the "SEC") a shelf registration statement on Form S-3 (File No. 333-288616), which became
03-27 04:45
iSpecimen Collects 500 Influenza Samples, Showcases Rapid Research Support
iSpecimen Inc. (NASDAQ:ISPC) (the "Company"), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the responsiveness and capabilities of its site
03-16 19:50
Century Therapeutics Q4 EPS $(0.25) Beats $(0.27) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 8.42 percent. This is a 41.86 percent increase over losses of $(0.43) per share
03-12 20:21
美股牛股 | 获FDA支持加速药物上市！MoonLake大涨27%；Satellogic大涨21.7%
获FDA支持加速药物上市！MoonLake大涨27%；宣布获七位数地球观测合同，Satellogic涨超21%>>
01-09 16:01
